7-Ethylcamptothecin: A Potent Topoisomerase I Inhibitor for Advanced Cancer Therapies

Exploring the cytotoxic potential and therapeutic applications of a key pharmaceutical intermediate.

Get a Quote & Sample

Key Advantages

Enhanced Cytotoxicity

Possesses significantly higher cytotoxicity against tumor cells, making it a valuable component in potent drug formulations. The pursuit to buy 7-Ethylcamptothecin fuels research into more effective cancer treatments.

Active Metabolite Insight

As the active metabolite of Irinotecan (SN-38), it provides critical data for understanding drug metabolism and optimizing chemotherapy regimens, aiding the study of the 7-ethyl-10-hydroxycamptothecin mechanism of action.

Research & Development Focus

Essential for preclinical studies and the development of novel cancer therapeutics, driving innovation in antineoplastic drug discovery by providing a reliable 7-Ethylcamptothecin CAS 78287-27-1 supplier.

Key Applications

Oncology Drug Development

Used in research for developing novel antineoplastic agents and understanding cancer cell responses to topoisomerase I inhibition, reflecting the 7-Ethylcamptothecin synthesis and antitumor activity research.

Pharmaceutical Intermediate

Serves as a critical intermediate in the synthesis of complex drug molecules, contributing to the broader pharmaceutical intermediate market and research into potent compounds.

Biochemical Research Tool

Valuable for in vitro and in vivo studies investigating drug efficacy, resistance mechanisms, and the detailed 7-ethyl-10-hydroxycamptothecin mechanism of action in various cancer models.

Reference Standard

Functions as a reference standard in analytical chemistry for quality control of Irinotecan and related compounds, ensuring the integrity of pharmaceutical products.